RTW Investments, LP

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves
  • APGEAPGE

    APOGEE THERAPEUTICS

    Sold out

    was 2.3% of portfolio

  • RARERARE

    Ultragenyx Pharmaceutical

    2.1× the shares

    now 2.2% of portfolio

  • COGTCOGT

    Cogent Biosciences

    Cut 58%

    now 0.8% of portfolio

  • CGONCGON

    CG Oncology

    Added 22%

    now 5.2% of portfolio

56 changes in all

Top Holdings84 positions

Checking export access…
Activity:
MDGL

Madrigal Pharmaceuticals, Inc.

2M$1.1B9.1%$265.94+101.91%
13 qtrssince 2023-Q2
Unchanged
0
ARGX
ARGX
ADR

argenx SE

709,446$658.2M5.6%$374.99+147.41%
30 qtrssince 2019-Q1
Unchanged
0
PTCT

PTC Therapeutics, Inc.

7.7M$631.9M5.4%$43.61+87.03%
30 qtrssince 2019-Q1
Unchanged
0
PTGX

Protagonist Therapeutics, Inc.

5.1M$620.4M5.3%$24.34+403.60%
28 qtrssince 2019-Q3
Increased
61
CGON

CG Oncology, Inc.

8.5M$605M5.2%$60.59+17.26%
10 qtrssince 2024-Q1
Increased
74
INSM

Insmed Incorporated

4.8M$516.3M4.4%$92.32+15.48%
13 qtrssince 2023-Q2
Unchanged
0
TNGX

Tango Therapeutics, Inc.

13.9M$434.5M3.7%$20.07+55.74%
3 qtrssince 2025-Q4
Increased
60
SYRE

Spyre Therapeutics, Inc.

4.3M$377.5M3.2%$24.87+256.98%
11 qtrssince 2023-Q4
Increased
58
CELC

Celcuity Inc.

3.3M$345.8M3.0%$110.98-5.73%
3 qtrssince 2025-Q4
Increased
58
ERAS

Erasca, Inc.

17.9M$328.8M2.8%$16.29+12.45%
3 qtrssince 2025-Q4
Increased
59
RDNT

RadNet, Inc.

4.8M$298.9M2.6%$56.57+9.01%
11 qtrssince 2023-Q4
Increased
60
ORKA

Oruka Therapeutics, Inc.

3.1M$298.7M2.6%$48.89+94.65%
8 qtrssince 2024-Q3
Increased
74
NTRA

Natera, Inc.

1M$271.5M2.3%$42.81+534.10%
28 qtrssince 2019-Q3
Decreased
0
RARE

Ultragenyx Pharmaceutical Inc.

7.8M$260.3M2.2%$35.70-6.47%
19 qtrssince 2021-Q4
Increased
85
IRTC

iRhythm Holdings, Inc.

2.2M$259.6M2.2%$150.42-20.92%
3 qtrssince 2025-Q4
Increased
67
CYTK

Cytokinetics, Incorporated

2.9M$243.8M2.1%$31.73+168.50%
24 qtrssince 2020-Q3
Increased
55
KLRA

Kailera Therapeutics, Inc.

10.8M$237.4M2.0%$22.030.00%
1 qtr
New
79
ESTA

Establishment Labs Holdings Inc.

2.7M$227.9M1.9%$27.61+210.83%
30 qtrssince 2019-Q1
Unchanged
0
GH

Guardant Health, Inc.

1.5M$222.2M1.9%$56.44+165.81%
5 qtrssince 2025-Q2
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

1.3M$213.7M1.8%$132.65+27.06%
5 qtrssince 2025-Q2
Increased
57
$11.7B
AUM
84
Positions
Q2 2026
Filing
HI rating · 3.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$6,538,371,722-1.12516489216%
2025-Q2$7,021,315,1197.38629459342%
2025-Q3$8,116,139,08515.592861842%
2025-Q4$9,983,316,87623.0057391999%
2026-Q1$10,049,752,6000.665467447595%
2026-Q2$11,712,926,78416.549404251%
Activity profile
$ moved · Q2'26
New16%Increased52%Decreased7%Exited25%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.6 years
<1Q6%1-4Q35%1-2Y11%2Y+49%

RTW Investments, LP manages $11.7B across 84 positions as of Q2 2026. Top holdings: MDGL (9.1%), ARGX (5.6%), PTCT (5.4%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.

Top holdings by portfolio weight

Total AUM$12B
MDGL9.14%
ARGX5.62%
PTCT5.39%
PTGX5.30%
CGON5.16%
INSM4.41%
TNGX3.71%
SYRE3.22%
CELC2.95%
ERAS2.81%
Other2.55%

Portfolio allocation by GICS sector

Sectors2
Healthcare99.93%
Financial Services0.07%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(3.0 / 5.0)
Holdings P&L47
Conviction63
Concentration65
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
CMPSCMPSCOMPASS Pathways Plc
Q1 2025 → Q3 2026+7.8M shares+$124.5M
7Q
IMTXIMTXImmatics N.V.
Q1 2025 → Q3 2026+7M shares+$72.2M
5Q
REPLREPLReplimune Group, Inc.
Q3 2025 → Q3 2026+6.4M shares+$93.2M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used